加载中
NASDAQHealthcareMedical - Instruments & Supplies
最新数据
US$52.45
−US$1.36 · -2.53%
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
收盘时
US$52.45
−US$1.36 · -2.53%
盘中时间采用ET。市场数据可能有所延迟。
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
日内区间
当前US$52.45
52周区间
当前US$52.45
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
13
估值过高
情绪
63
看涨
风险
57
风险偏高
动量
62
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
日内区间
当前US$52.45
52周区间
当前US$52.45
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 35万 USD | — | — | 70万 USD | 141.8万 USD |
| 销货成本 | 161万 USD | — | 120.7万 USD | 1194.4万 USD | 196.8万 USD |
| 毛利 | −126万 USD | — | −120.7万 USD | −1124.4万 USD | −55万 USD |
| 研究与开发 | 4472.1万 USD | 3233.6万 USD | 2779.7万 USD | 2083.9万 USD | 2864万 USD |
| 销售、一般及管理费用 | 3202.9万 USD | 2392.1万 USD | 1577.7万 USD | 2597.4万 USD | 3382.4万 USD |
| 营业费用 | 7567.9万 USD | 5625.7万 USD | 4236.7万 USD | 4681.3万 USD | 6246.4万 USD |
| 利息收入 | 421万 USD | 267.2万 USD | 246.4万 USD | — | — |
| 利息支出 | — | — | 110万 USD | 44.8万 USD | 64.6万 USD |
| 折旧和摊销 | 107.1万 USD | 117.8万 USD | 120.7万 USD | 135.5万 USD | 114.6万 USD |
| 营业利润 | −7693.9万 USD | −5625.7万 USD | −4357.4万 USD | −5805.7万 USD | −6301.4万 USD |
| 净利润 | −7278.1万 USD | −5358.5万 USD | −4221万 USD | −5850.5万 USD | −6366万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$53.20
上涨空间 1.43%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2791.36万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM2657.02万0.03%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF1087.54万0.01%954亿 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO934.12万0.07%139.17亿 USD0.24%US$353.71-0.86%
Schwab U.S. Small-Cap ETFSCHA571.86万0.03%218.24亿 USD0.03%US$32.66-0.40%
Vanguard Russell 2000 ETFVTWO536.95万0.03%180亿 USD0.06%US$112.27-0.35%
iShares U.S. Medical Devices ETFIHI531.99万0.15%35.74亿 USD0.37%US$52.79+2.03%
Invesco Dorsey Wright Healthcare Momentum ETFPTH333.32万1.16%2.87亿 USD0.74%US$58.3797-0.65%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAVanguard Russell 2000 ETFVTWOiShares U.S. Medical Devices ETFIHIInvesco Dorsey Wright Healthcare Momentum ETFPTHAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
